Related references
Note: Only part of the references are listed.A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15
Claire L. Sutherland et al.
BLOOD (2006)
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
EJ Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy
K Takeda et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-D33 monoclonal antibody HuM195
E Feldman et al.
LEUKEMIA (2003)
Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotug) therapy
P Rajvanshi et al.
BLOOD (2002)
CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
N Selenko et al.
LEUKEMIA (2001)
Share Paper
